LinkedIn
WebsiteBionano Genomics Inc: Company Overview
Bionano Genomics Inc (NASDAQ: BNGO) develops optical genome mapping (OGM) systems and software for detecting structural variants in DNA and RNA. Headquartered in San Diego, California, the company’s Stratys and Saphyr platforms are utilized in applications across oncology, rare disease diagnostics, and basic research. Its ticker symbol is BNGO, and the shares trade on the Nasdaq Stock Market. As of the market close on 2025-09-15, the share price was $1.57, a 43.32% decrease from the prior trading day, with a daily volume of 702,958 shares.
Corporate Structure and Workforce
Bionano Genomics employs approximately 201 to 500 people worldwide. The leadership team comprises R&D scientists, software engineers, and commercial professionals. Profiles on LinkedIn indicate collaborations with academic centers, including Radboudumc in the Netherlands. Executives like Mark Oldakowski, with a background at Affymetrix, highlight the company's focus on product performance improvements and program management.
Optical genome mapping by Ricardo Gomez Angel
Recent Developments
- On 2025-09-11, Bionano filed a Form S-1 registration statement (CIK 0001411690) with the U.S. Securities and Exchange Commission, detailing the intended use of proceeds for R&D, market expansion, and strengthening the balance sheet.
- On 2025-08-14, the company filed its Form 10-Q for the quarter ending 2025-06-30 and a Form 8-K reporting significant events, including updates on liquidity and strategic priorities.
- For the third quarter of fiscal 2024 (ended 2024-09-30), management reported a 69% reduction in GAAP operating expenses and a 49% decrease in non-GAAP operating expenses year-over-year, alongside a 27% increase in flow-cell sales. This was offset by a 35% decline in revenue, partly due to the discontinuation of certain clinical services.
- Following the release of full-year results prior to 2025-09-15, analysts upgraded Bionano’s 2025 revenue forecast to $30.3 million (from $28.8 million) and narrowed the projected per-share loss to $6.00 (from $12.60), while the consensus price target was adjusted to $4.00.
Financial and Strategic Analysis
As of 2025-09-15, Bionano’s trailing twelve-month figures include revenue of $27.43 million, a net loss of $74.33 million, and total cash of $16.44 million. Key ratios from Yahoo Finance are:
| Metric | Value |
|---|---|
| Market Cap (intraday) | $13.48 M |
| Price/Sales (TTM) | 0.33 |
| Price/Book (MRQ) | 0.40 |
| Profit Margin | –271.02% |
| Debt/Equity (MRQ) | 43.15% |
Strategically, the company is focusing on:
- Expanding consumables revenue through a new go-to-market strategy targeting 150 high-volume accounts.
- Securing reimbursement through a new CPT code for OGM.
- Launching the Ionic G2 sample preparation system for faster DNA/RNA isolation, with commercial rollout anticipated after 2025.
- Managing cash burn by streamlining operations and reducing inventory write-downs associated with discontinued services.
Market Position and Industry Context
Optical genome mapping represents a niche within the larger genomics market, competing against next-generation sequencing (NGS) and classical cytogenetics. Industry data suggest aggregate revenue growth of approximately 5.8% annually through 2025, while analysts forecast Bionano’s revenue to slightly decline at a CAGR of -1.7% over the same period. With a beta of 2.26, the stock demonstrates above-average volatility. The company’s relatively small market capitalization and ongoing net losses reflect challenges compared to larger, diversified genomics firms, although its specialized OGM platform serves as a differentiating factor in structural variant analysis.
tl;dr
On 2025-09-11, Bionano filed an S-1 outlining intended capital uses for R&D and market expansion. As of 2025-09-15, the share price fell 43.32% to $1.57. For Q3 2024 (ended 2024-09-30), the company reduced GAAP operating expenses by 69% but saw revenue drop 35% year-over-year. Analysts now anticipate 2025 revenue of $30.3 million and a per-share loss of $6.00. Market growth for structural-variant analysis tools is expected to be below broader genomics growth, with Bionano’s revenue forecast reflecting a slight decline compared to a 5.8% industry CAGR.
